Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
FATE - Fate Therapeutics, Inc.
Market Cap 369.93M P/E - EPS this Y -3.00% Ern Qtrly Grth -
Income -175.72M Forward P/E -1.88 EPS next Y 0.60% 50D Avg Chg -24.00%
Sales 12.32M PEG 0.05 EPS past 5Y - 200D Avg Chg -58.00%
Dividend N/A Price/Book 0.77 EPS next 5Y -37.30% 52W High Chg -90.00%
Recommedations 2.60 Quick Ratio 8.84 Shares Outstanding 113.88M 52W Low Chg 1.00%
Insider Own 2.17% ROA -20.50% Shares Float 90.26M Beta 1.84
Inst Own 108.53% ROE -42.10% Shares Shorted/Prior 15.04M/13.93M Price 3.76
Gross Margin - Profit Margin - Avg. Volume 2,181,370 Target Price 6.58
Oper. Margin -665.73% Earnings Date Nov 6 Volume 2,226,209 Change -5.29%
Healthcare | Biotechnology | United States
About Fate Therapeutics, Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics, Inc. News
11/18/24 Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results
11/18/24 Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
11/18/24 Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
11/15/24 Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
11/14/24 Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations
11/13/24 FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
11/12/24 Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
11/12/24 Fate Therapeutics: Q3 Earnings Snapshot
11/12/24 Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
11/09/24 Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
11/08/24 Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
11/04/24 Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
10/02/24 Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
09/12/24 Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
09/12/24 Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?
08/22/24 Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher
08/16/24 All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy
08/15/24 Fate Therapeutics Second Quarter 2024 Earnings: Beats Expectations
08/14/24 FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow
08/13/24 Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
FATE Chatroom

User Image Handstiedbull Posted - 1 hour ago

$FATE

User Image youbi336 Posted - 20 hours ago

$FATE I invest in its competitor $NKTX but follow this closely. Why is the price target so low on this one? Seems to have a lot of potential...

User Image mplaster Posted - 1 day ago

$FATE time for this to rip faces off

User Image giuseppe8469 Posted - 1 day ago

$FATE no market pullback thats all folks up we go you should have bean buying or adding on that pullback sellers made mistake

User Image piano91 Posted - 1 day ago

$FATE Shorts have time until 10 December when they present data from 3 Lupus cures then market will price it in. Guess one patient was not enough but it's just 3 weeks away

User Image Jacobroon97 Posted - 1 day ago

$FATE

User Image pahan4k Posted - 1 day ago

$FATE

User Image mplaster Posted - 1 day ago

$FATE this stinks of shit ..still in though

User Image TozerMax Posted - 1 day ago

$FATE Right back to the downtrend on the daily chart.

User Image pahan4k Posted - 1 day ago

$FATE almost all time low, strong by opportunity

User Image giuseppe8469 Posted - 1 day ago

$FATE 2.05 add

User Image giuseppe8469 Posted - 1 day ago

$FATE huge add for me thats close enough for the gap fill for my liking

User Image Stephan1988 Posted - 1 day ago

$FATE good news yesterday, but almost at All time low 😅

User Image aw20 Posted - 1 day ago

$FATE and it's halted by my broker in Germany since this morning. What is this criminal ish 😒

User Image mplaster Posted - 1 day ago

$FATE this is just ridiculous ... It would cure cancer and still tank ...

User Image pahan4k Posted - 1 day ago

$FATE

User Image Etrading Posted - 2 days ago

$FATE low $2s or little under .. buy dips sell the rips...

User Image pahan4k Posted - 2 days ago

$FATE buy now before it is late, will blow soon

User Image Kenco1 Posted - 2 days ago

$FATE I'm bullish but this is getting ridiculous

User Image pahan4k Posted - 2 days ago

$FATE it will blow up soon

User Image cbryant025 Posted - 2 days ago

$FATE BOOM SHORTY!!

User Image mplaster Posted - 2 days ago

$FATE short squeeze time for parabolic activity

User Image cbryant025 Posted - 2 days ago

$FATE the volume is the highest I have ever seen it!

User Image cbryant025 Posted - 2 days ago

$FATE thank shorties

User Image Pianomemo Posted - 2 days ago

$FATE Just buy and hold you’ll see it will double in value. Market has to price it in and shake off the shorts

User Image pahan4k Posted - 2 days ago

$FATE

User Image rxptgh Posted - 2 days ago

$FATE trading below cash 💰

User Image tradingtwenty Posted - 2 days ago

Top 5 after-hours stocks that have trended in the past 24 hours: $SMCI 39.79% 🔥 $SYM 26.31% $BKKT 17.03% $FATE 9.25% $HCWB 8.87% Link: https://tradingtwenty.com/dashboard/trending/past

User Image Ned_Nosurname Posted - 2 days ago

$FATE https://www.globenewswire.com/news-release/2024/11/18/2982736/24675/en/Fate-Therapeutics-Highlights-FT522-Off-the-shelf-ADR-armed-CAR-NK-Cell-Product-Candidate-at-2024-ACR-Convergence.html

User Image Ned_Nosurname Posted - 2 days ago

$FATE https://www.globenewswire.com/news-release/2024/11/18/2982757/0/en/Fate-Therapeutics-Presents-6-Month-Follow-up-Data-on-First-Patient-Treated-in-Phase-1-Autoimmunity-Study-with-Fludarabine-free-Conditioning-and-FT819-Off-the-shelf-1XX-CAR-T-cell-P.html

Analyst Ratings
HC Wainwright & Co. Neutral Aug 22, 24
Needham Hold Aug 14, 24
Piper Sandler Overweight Jun 17, 24
HC Wainwright & Co. Neutral May 16, 24
Canaccord Genuity Buy May 10, 24
BMO Capital Market Perform May 10, 24
Wedbush Neutral May 10, 24
Piper Sandler Neutral May 10, 24
Wedbush Neutral May 6, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
TAHL CINDY General Counsel and.. General Counsel and Secretary Jan 09 Sell 4.37 10,874 47,519 142,361 01/10/24
Redmile Group, LLC Director Director Dec 26 Buy 3.72 44,630 166,024 13,180,388 12/28/23
Powl Brian T. Chief Commercial Off.. Chief Commercial Officer Jul 05 Sell 4.87 3,854 18,769 41,146 07/06/23
Dulac Edward J III Chief Financial Offi.. Chief Financial Officer Jul 05 Sell 4.83 5,182 25,029 124,288 07/06/23
Xu Yuan Director Director Jun 14 Sell 5.58 3,460 19,307 9,934 06/15/23
Redmile Group, LLC Director Director Apr 20 Buy 6.09 276,639 1,684,732 13,135,758 04/21/23
Redmile Group, LLC Director Director Apr 13 Sell 5.84 302,339 1,765,660 12,833,419 04/17/23
Redmile Group, LLC Director Director Apr 13 Buy 6 25,700 154,200 12,859,119 04/17/23
MENDLEIN JOHN Director Director Jan 11 Buy 5.55 124,679 691,968 282,770 01/13/23
Dulac Edward J III Chief Financial Offi.. Chief Financial Officer Aug 18 Sell 30.08 5,135 154,461 136,801 08/19/22
Wolchko J Scott President and CEO President and CEO Jul 21 Option 2.7 36,246 97,864 437,792 07/25/22
Wolchko J Scott President and CEO President and CEO Jul 21 Sell 32.57 36,246 1,180,532 431,546 07/25/22
Valamehr Bahram Chief R&D Officer Chief R&D Officer Jul 07 Option 2.73 17,158 46,841 196,992 07/08/22
Valamehr Bahram Chief R&D Officer Chief R&D Officer Jul 07 Sell 30.23 17,158 518,686 179,834 07/08/22
Valamehr Bahram Chief R&D Officer Chief R&D Officer Jul 06 Option 3.79 7,842 29,721 187,676 07/07/22
Valamehr Bahram Chief R&D Officer Chief R&D Officer Jul 06 Sell 30.07 7,842 235,809 179,834 07/07/22
Agarwal Shefali Director Director Jun 07 Sell 21.89 841 18,409 1,840 06/08/22
Agarwal Shefali Director Director Jun 03 Sell 0.00 2,681 06/08/22
Wolchko J Scott President and CEO President and CEO Apr 21 Sell 35.77 40,000 1,430,800 431,546 04/25/22
Wolchko J Scott President and CEO President and CEO Apr 21 Option 2.7 40,000 108,000 441,546 04/25/22
Valamehr Bahram Chief R&D Officer Chief R&D Officer Mar 14 Option 2.73 25,000 68,250 204,834 03/15/22
Valamehr Bahram Chief R&D Officer Chief R&D Officer Mar 14 Sell 32.37 25,000 809,250 179,834 03/15/22
MENDLEIN JOHN Director Director Mar 10 Option 1.63 31,562 51,446 191,017 03/11/22
MENDLEIN JOHN Director Director Mar 10 Sell 35.11 31,562 1,108,142 159,455 03/11/22
Wolchko J Scott President and CEO President and CEO Jan 20 Option 2.70 30,000 81,000 461,546 02/04/22
Wolchko J Scott President and CEO President and CEO Jan 11 Sell 48.79 14,566 710,675 431,546 01/13/22
TAHL CINDY General Counsel and.. General Counsel and Secretary Jan 11 Sell 48.81 5,419 264,501 155,849 01/13/22
Valamehr Bahram Chief R&D Officer Chief R&D Officer Jan 11 Sell 48.78 4,570 222,925 146,532 01/13/22
Dulac Edward J III Chief Financial Offi.. Chief Financial Officer Jan 11 Sell 48.71 1,770 86,217 108,634 01/13/22
Chu Yu-Waye Senior VP Clinical D.. Senior VP Clinical Development Jan 11 Sell 48.77 3,965 193,373 121,793 01/13/22
Wolchko J Scott President and CEO President and CEO Jan 10 Sell 47.08 34,156 1,608,064 446,112 01/12/22
TAHL CINDY General Counsel and.. General Counsel and Secretary Jan 10 Sell 46.76 7,738 361,829 161,268 01/12/22
Valamehr Bahram Chief R&D Officer Chief R&D Officer Jan 10 Sell 46.75 5,596 261,613 151,102 01/12/22
Chu Yu-Waye Senior VP Clinical D.. Senior VP Clinical Development Dec 10 Option 16.32 7,500 122,400 133,258 12/13/21
Chu Yu-Waye Senior VP Clinical D.. Senior VP Clinical Development Dec 10 Sell 52.42 7,500 393,150 125,758 12/13/21
Wolchko J Scott President and CEO President and CEO Nov 18 Option 2.7 20,000 54,000 413,793 11/22/21
Wolchko J Scott President and CEO President and CEO Nov 18 Sell 54.27 20,000 1,085,400 393,793 11/22/21
Wolchko J Scott President and CEO President and CEO Feb 19 Option 6.62 20,000 132,400 413,793 02/19/21
Wolchko J Scott President and CEO President and CEO Jan 22 Option 4.03 60,000 241,800 423,793 01/22/21
Wolchko J Scott President and CEO President and CEO Jan 22 Sell 101.98 60,000 6,118,800 393,793 01/22/21
TAHL CINDY General Counsel and.. General Counsel and Secretary Jan 21 Option 2.9 35,000 101,500 125,035 01/21/21
TAHL CINDY General Counsel and.. General Counsel and Secretary Jan 21 Sell 115.56 35,000 4,044,600 90,035 01/21/21
Wolchko J Scott President and CEO President and CEO Jan 12 Sell 113.91 69,407 7,906,151 350,562 01/12/21
Valamehr Bahram Chief Development Of.. Chief Development Officer Jan 12 Sell 113.91 9,484 1,080,322 77,727 01/12/21
TAHL CINDY General Counsel and.. General Counsel and Secretary Jan 12 Sell 113.91 9,483 1,080,209 90,035 01/12/21
Shoemaker Daniel D Chief Scientific Off.. Chief Scientific Officer Jan 12 Sell 113.91 9,482 1,080,095 83,609 01/12/21
Shoemaker Daniel D Chief Scientific Off.. Chief Scientific Officer Nov 16 Sell 51.46 25,000 1,286,500 93,091 11/16/20
Wolchko J Scott President and CEO President and CEO Nov 16 Option 4.99 60,000 299,400 430,123 11/16/20
Wolchko J Scott President and CEO President and CEO Nov 16 Sell 52.26 60,000 3,135,600 419,969 11/16/20
TAHL CINDY General Counsel and.. General Counsel and Secretary Nov 06 Option 2.79 70,801 197,535 118,800 11/06/20